-
公开(公告)号：US20110086026A1
公开(公告)日：2011-04-14
申请号：US12843225
申请日：2010-07-26
申请人： Josef Endl , Maria Elena Fuentes , Yvo Graus , Adelbert Grossmann , Sebastian Neumann , Paul Parren , Frank Rebers , Joerg Thomas Regula , Ralf Schumacher , Stefan Seeber , Jan Olaf Stracke , Kay-Gunnar Stubenrauch , Jan Van De Winkel , Martine Van Vugt , Sandra Vereecken-Verploegen
发明人： Josef Endl , Maria Elena Fuentes , Yvo Graus , Adelbert Grossmann , Sebastian Neumann , Paul Parren , Frank Rebers , Joerg Thomas Regula , Ralf Schumacher , Stefan Seeber , Jan Olaf Stracke , Kay-Gunnar Stubenrauch , Jan Van De Winkel , Martine Van Vugt , Sandra Vereecken-Verploegen
IPC分类号： A61K39/395 , C07H21/00 , C07K16/00 , A61P11/06 , A61P37/02 , C12N5/10 , C12P21/02 , C12N15/63 , C12N1/00
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/56 , C07K2317/76
摘要： An antibody binding to IL-13Rα1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.
摘要翻译： 与IL-13Rα1结合的抗体，抑制IL-13生物活性并包含可变重链和可变轻链的抗体，其特征在于所述抗体的可变重链氨基酸序列CDR3选自重链CDR3序列 的SEQ ID NO：1,3,5,7或9可用于治疗哮喘和过敏性疾病。
-
公开(公告)号：US07807158B2
公开(公告)日：2010-10-05
申请号：US11325197
申请日：2006-01-03
申请人： Josef Endl , Maria Elena Fuentes , Yvo Graus , Adelbert Grossmann , Sebastian Neumann , Paul Parren , Frank Rebers , Joerg Thomas Regula , Ralf Schumacher , Stefan Seeber , Jan Olaf Stracke , Kay-Gunnar Stubenrauch , Jan Van De Winkel , Martine Van Vugt , Sandra Vereecken-Verploegen
发明人： Josef Endl , Maria Elena Fuentes , Yvo Graus , Adelbert Grossmann , Sebastian Neumann , Paul Parren , Frank Rebers , Joerg Thomas Regula , Ralf Schumacher , Stefan Seeber , Jan Olaf Stracke , Kay-Gunnar Stubenrauch , Jan Van De Winkel , Martine Van Vugt , Sandra Vereecken-Verploegen
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/56 , C07K2317/76
摘要： The instant specification discloses an antibody binding to IL-13Rα1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of this antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9, and this antibody is useful in the treatment of asthma and allergic diseases.
摘要翻译： 本说明书公开了结合IL-13Rα1的抗体，抑制IL-13生物活性并包含可变重链和可变轻链，其特征在于该抗体的可变重链氨基酸序列CDR3选自 SEQ ID NO：1,3,5,7或9的重链CDR3序列，该抗体可用于治疗哮喘和过敏性疾病。
-
公开(公告)号：US20060263356A1
公开(公告)日：2006-11-23
申请号：US11325197
申请日：2006-01-03
申请人： Josef Endl , Maria Fuentes , Yvo Graus , Adelbert Grossmann , Sebastian Neumann , Paul Parren , Frank Rebers , Joerg Regula , Ralf Schumacher , Stefan Seeber , Jan stracke , Kay-Gunnar Stubenrauch , Jan Van De Winkel , Martine Van Vugt , Sandra Vereecken-Verploegen
发明人： Josef Endl , Maria Fuentes , Yvo Graus , Adelbert Grossmann , Sebastian Neumann , Paul Parren , Frank Rebers , Joerg Regula , Ralf Schumacher , Stefan Seeber , Jan stracke , Kay-Gunnar Stubenrauch , Jan Van De Winkel , Martine Van Vugt , Sandra Vereecken-Verploegen
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C12N5/06
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/56 , C07K2317/76
摘要： An antibody binding to IL-13Rα1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.
摘要翻译： 与IL-13Rα1结合的抗体，抑制IL-13生物活性并包含可变重链和可变轻链，其特征在于所述抗体的可变重链氨基酸序列CDR3选自重链CDR3序列 的SEQ ID NO：1,3,5,7或9可用于治疗哮喘和过敏性疾病。
-
公开(公告)号：US09102733B2
公开(公告)日：2015-08-11
申请号：US12958278
申请日：2010-12-01
申请人： Joseph Endl , Elsie M. Eugui , Maria Elena Fuentes , Yvo Graus , Aran Frank Labrijn , Martin Lanzendoerfer , Paul Parren , Frank Rebers , Ralf Schumacher , Stefan Seeber , Jan Van De Winkel , Martine Van Vugt
发明人： Joseph Endl , Elsie M. Eugui , Maria Elena Fuentes , Yvo Graus , Aran Frank Labrijn , Martin Lanzendoerfer , Paul Parren , Frank Rebers , Ralf Schumacher , Stefan Seeber , Jan Van De Winkel , Martine Van Vugt
IPC分类号： C07K16/28
CPC分类号： C07K16/2875 , C07K2317/21 , C07K2317/52 , C07K2317/56
摘要： This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
-
公开(公告)号：US07868141B2
公开(公告)日：2011-01-11
申请号：US12315863
申请日：2008-12-05
申请人： Joseph Endl , Elsie M. Eugui , Maria Elena Fuentes , Yvo Graus , Aran Frank Labrijn , Martin Lanzendoerfer , Paul Parren , Frank Rebers , Ralf Schumacher , Stefan Seeber , Jan Van De Winkel , Martine Van Vugt
发明人： Joseph Endl , Elsie M. Eugui , Maria Elena Fuentes , Yvo Graus , Aran Frank Labrijn , Martin Lanzendoerfer , Paul Parren , Frank Rebers , Ralf Schumacher , Stefan Seeber , Jan Van De Winkel , Martine Van Vugt
IPC分类号： C07K16/00 , A61K39/395
CPC分类号： C07K16/2875 , C07K2317/21 , C07K2317/52 , C07K2317/56
摘要： This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
摘要翻译： 本发明涉及抗OX40L抗体，特别涉及抗OX40L抗体及其变体，其含有源自人源的Fc部分，并且不结合补体因子C1q。 这些抗体具有新的和本发明的性质，为患有炎性疾病的患者带来益处。
-
公开(公告)号：US20110070239A1
公开(公告)日：2011-03-24
申请号：US12958278
申请日：2010-12-01
申请人： Joseph Endl , Elsie M. Eugui , Maria Elena Fuentes , Yvo Graus , Aran Frank Labrijn , Martin Lanzendoerfer , Paul Parren , Frank Rebers , Ralf Schumacher , Stefan Seeber , Jan Van De Winkel , Martine Van Vugt
发明人： Joseph Endl , Elsie M. Eugui , Maria Elena Fuentes , Yvo Graus , Aran Frank Labrijn , Martin Lanzendoerfer , Paul Parren , Frank Rebers , Ralf Schumacher , Stefan Seeber , Jan Van De Winkel , Martine Van Vugt
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C12N5/074
CPC分类号： C07K16/2875 , C07K2317/21 , C07K2317/52 , C07K2317/56
摘要： This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
摘要翻译： 本发明涉及抗OX40L抗体，特别涉及抗OX40L抗体及其变体，其含有源自人源的Fc部分，并且不结合补体因子C1q。 这些抗体具有新的和本发明的性质，为患有炎性疾病的患者带来益处。
-
公开(公告)号：US07501496B1
公开(公告)日：2009-03-10
申请号：US11229162
申请日：2005-09-16
申请人： Joseph Endl , Elsie M. Eugui , Maria Elena Fuentes , Yvo Graus , Aran Frank Labrijn , Martin Lanzendoerfer , Paul Parren , Frank Rebers , Ralf Schumacher , Stefan Seeber , Jan Van De Winkel , Martine Van Vugt
发明人： Joseph Endl , Elsie M. Eugui , Maria Elena Fuentes , Yvo Graus , Aran Frank Labrijn , Martin Lanzendoerfer , Paul Parren , Frank Rebers , Ralf Schumacher , Stefan Seeber , Jan Van De Winkel , Martine Van Vugt
IPC分类号： C07K16/00 , C07K16/28 , A61K39/395
CPC分类号： C07K16/2875 , C07K2317/21 , C07K2317/52 , C07K2317/56
摘要： This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
摘要翻译： 本发明涉及抗OX40L抗体，特别涉及抗OX40L抗体及其变体，其含有源自人源的Fc部分，并且不结合补体因子C1q。 这些抗体具有新的和本发明的性质，为患有炎性疾病的患者带来益处。
-
公开(公告)号：US20090148449A1
公开(公告)日：2009-06-11
申请号：US11886932
申请日：2006-03-23
申请人： Michel De Weers , Yvo Graus , Judith Oprins , Paul Parren , Jan Van De Winkel , Martine Van Vugt
发明人： Michel De Weers , Yvo Graus , Judith Oprins , Paul Parren , Jan Van De Winkel , Martine Van Vugt
IPC分类号： A61K39/395 , C07K16/18 , C12N15/11 , C12N15/00 , C12N5/06 , G01N33/574 , A61K31/7088 , C12N1/21 , A01K67/027 , A01H5/00
CPC分类号： C07K16/40 , A61K39/3955 , A61K45/06 , A61K49/0004 , A61K2039/505 , C07K14/70596 , C07K16/2896 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/566 , G01N2333/70596
摘要： Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
摘要翻译： 公开了与人CD38结合的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 还公开了包含人抗体的药物组合物，以及使用人抗体的治疗和诊断方法。
-
公开(公告)号：US09187565B2
公开(公告)日：2015-11-17
申请号：US12886930
申请日：2010-09-21
申请人： Michel De Weers , Yvo Graus , Judith Oprins , Paul Parren , Jan Van De Winkel , Martine Van Vugt
发明人： Michel De Weers , Yvo Graus , Judith Oprins , Paul Parren , Jan Van De Winkel , Martine Van Vugt
IPC分类号： A61K38/00 , C07K16/28 , C07K14/705 , A61K39/00
CPC分类号： C07K16/40 , A61K39/3955 , A61K45/06 , A61K49/0004 , A61K2039/505 , C07K14/70596 , C07K16/2896 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/566 , G01N2333/70596
摘要： Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
-
公开(公告)号：US09040050B2
公开(公告)日：2015-05-26
申请号：US12442808
申请日：2007-09-26
申请人： Jan Van De Winkel , Paul Parren , Yvo Graus , Judith Oprins , Michel De Weers , Martine Van Vugt , Ole Baadsgaard , Steen Lisby
发明人： Jan Van De Winkel , Paul Parren , Yvo Graus , Judith Oprins , Michel De Weers , Martine Van Vugt , Ole Baadsgaard , Steen Lisby
IPC分类号： A61K39/395 , C07K16/28 , A61K45/06 , A61K39/00
CPC分类号： C07K16/2896 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K2317/34 , A61K2300/00
摘要： The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.
摘要翻译： 本发明涉及使用包含结合CD38的抗体，皮质类固醇和非皮质类固醇化学治疗剂的组合疗法治疗癌症的新方法。
-
-
-
-
-
-
-
-
-
搜索结果
43 条记录 (耗时 0.065 秒)
